Coronavirus
Germany Approves First Human Trials Of Covid-19 Vaccine
Germany has approved first clinical trials of a COVID-19 vaccine on humans.
Biotechnology company BioNTech’s vaccine program was authorized for human clinical trials after a careful assessment of potential risks and benefits, the Paul-Ehrlich-Institut, German regulatory authority, said in a press release.
“This is the fourth authorized clinical trial worldwide in which a preventive specific COVID-19 vaccine candidate is tested in humans,” the institute stressed, and added:
“Considering the serious consequences of the COVID-19 pandemic, this is a significant step toward developing an efficacious and safe COVID-19 vaccine available in Germany and making it available worldwide as soon as possible.”
Turkish professor Ugur Sahin’s BioNTech company and pharma giant Pfizer are jointly developing vaccine candidates, as part of a global development program.
“We are pleased to have completed pre-clinical studies in Germany and will soon initiate this first-in-human trial ahead of our expectations. The speed with which we were able to move from the start of the program to trial initiation speaks to the high level of engagement from everyone involved,” Sahin said in a statement.
In the authorized first part of the clinical trial in Germany, 200 healthy volunteers aged between 18 and 55 years will be vaccinated, according to the Paul-Ehrlich-Institut.
Further trials involving people with increased infection risk planned for the second part of the clinical trial, on condition that additional study data submitted in advance.
Scientists and researchers across the world are scrambling to find a vaccine for the novel coronavirus which has infected over 2.58 million people worldwide and killed more than 178,000.
Until such a discovery, health experts are treating patients with anti-malaria drugs, including hydroxychloroquine and chloroquine, which have shown positive results for coronavirus-related lung infection.
So far nearly 693,000 coronavirus patients worldwide have recovered from the disease.
Kenya Insights allows guest blogging, if you want to be published on Kenya’s most authoritative and accurate blog, have an expose, news TIPS, story angles, human interest stories, drop us an email on [email protected] or via Telegram
-
Business2 weeks agoSold And Abandoned: How Diageo and Asahi Are Locking Kenya’s EABL Minority Shareholders Out Of East Africa’s Biggest Corporate Heist
-
Business2 weeks agoPoison at the Pump: How Kenya’s Fuel Marking System May Be Exposing Millions to Cancer-Causing Chemicals
-
Investigations1 week agoThe Teflon Company: How Gulf Energy’s Insiders Built Billions on Kenya’s Fuel, and Walked Away Clean
-
Investigations1 week agoTHE ZAKHEM-ECOBANK MACHINE: How Kenya’s Courts Were Weaponised to Drain a State Corporation of Over KES 78 Billion
-
Investigations1 week agoInside Details Of Sh78 Billion Fraud in KPC’s Mombasa-Nairobi Line 5 Pipeline Project That Has Continued To Bleed The Country
-
News7 days agoMombasa Lawyer Exposed In Sh600 Million Alleged Double-Dealing Diani Property Transaction
-
Investigations2 weeks agoInside Nyayo House: The Kitchen Cartel That Demands Sh100,000 for a Stove
-
News2 weeks agoTreasury Hands Sh358M Brief to Eric Gumbo’s Firm While Bypassing Standard Rules — and the Lawyer Is Already Deep Inside Ruto’s State Machine
